Background: HIV elite controllers suppress HIV viremia without antiretroviral therapy (ART), yet previous studies demonstrated that elite controllers maintain an activated T-cell phenotype. Chronic immune activation has detrimental consequences and thus ART has been advocated for all elite controllers. However, elite controllers are not a clinically homogenous group. Since CD4% is among the best predictors of AIDS-related events, in the current study, we assessed whether this marker can be used to stratify elite controllers needing ART.
Introduction
A minority of HIV-infected individuals (less than 1% of the total HIV-infected population) control HIV with low or undetectable plasma viral loads (pVL) in the absence of antiretroviral treatment (ART). These rare individuals, Notably, polyfunctional T cells, capable of cytokine secretion, proliferation, and cytotoxicity, are maintained in these controllers [4] [5] [6] [7] [8] [9] . Additional important aspects of their T-cell function have been reported, including low levels of T-cell activation [10] , upregulation of survival factors such as bcl-2 [11] , upregulation of cyclindependent kinase inhibitors such as p21 [12] and higher frequency of expression of costimulatory molecule CD73 [13] . Furthermore, cells from elite controllers are less susceptible to infection and effectively suppress in-vitro HIV replication [8, 14] . The elite controllers group is also enriched for HLA-B Ã 27 and B Ã 57 alleles that have been associated with protection from HIV disease progression [15, 16] .
Despite these advantages, elite controllers fail to clear HIV infection. Ultra-sensitive assays measuring pVL indicate that residual pVL remains higher in some elite controllers than in ART-treated individuals [17, 18] . Additionally, CD4 þ cells from elite controllers can harbor pathogenic replication competent virus that may contribute to excess T-cell activation [19, 20] . Interestingly a recent simian immunodeficiency virus study suggested that effector CD8 þ T cells are unable to access B-cell follicles and target-infected T follicular helper cells. The latter probably serves as a viral reservoir responsible for the low-level and persistent antigenemia [21] . Alterations in innate immune function have also been reported in elite controllers with increased inflammatory monocytes compared with HIV-uninfected controls [22] . Recently, elite controllers have also been shown to have elevated levels of key soluble inflammatory markers [23] and higher hospitalization rates than ART-treated individuals [24] .
Upregulation of T-cell immune activation markers (CD38, HLA-DR and/or Ki67) is a well-described feature of chronic HIV infection [10, 25, 26] linked with disease progression [10, 27] . It is likely that low-level viremia is one factor contributing to elevated innate and adaptive immune activation in elite controllers that remains higher than HIV-1 seronegative and ART-treated individuals [10, 18] . However, even with suppressive ART, key markers of immune activation are not reduced to levels that are on par with HIV-1 seronegative individuals. As a consequence, despite being on ART, HIV-infected individuals are at increased risk of inflammation associated comorbidities [10, 28, 29] .
Since persistent immune activation and the ensuing inflammation can have detrimental consequences, it has thus been suggested all elite controllers may benefit from ART [19, 30] . However, HIV controllers are not a homogenous group [31] [32] [33] [34] whereby some individuals maintain absolute CD4 þ cell counts over time whereas others display activation-induced loss [10, 35, 36] . Furthermore, a prior study demonstrated an inverse correlation between absolute CD4 þ T-cell counts and T-cell immune activation [10] suggesting a dynamic range in immune activation within HIV controllers. A discriminatory marker to identify elite controllers who are more likely to have persistent immune dysfunction would aid clinicians in assessing who may benefit the most from early ART initiation.
CD4% has been used to stratify individuals needing ART since it is among the best predictors of AIDS-related events [37] [38] [39] [40] . We, therefore, assessed expression levels of immune activation/exhaustion markers on T cells based on the CD4% of HIV-infected patients. Elite controllers with preserved CD4 þ T-cell percentages (EC hi ) had significantly lower levels of activated/ exhausted HIV-specific CD8 þ T cells than elite controllers with low CD4 þ T-cell percentages (EC lo ) and the former mirrored the seronegative controls. Based on these results, EC lo may benefit the most by initiating ARTor other inflammation reducing treatments whereas no evidence was obtained to suggest that such treatments would benefit the EC hi group.
Materials and methods

Study cohort
Cryopreserved peripheral blood mononuclear cells (PBMC) and plasma samples from 25 HIV-1-infected patients receiving care at the 1917 clinic at the University of Alabama at Birmingham and eight HIV-1 seronegative volunteers enrolled in the Alabama Vaccine Research Clinic at University of Alabama at Birmingham (UAB) were used in this study. All HIV-infected patients were off ART. The elite controllers used in this study met the criteria of consecutive undetectable HIV-RNA measurements for greater than six months or with greater than 90% of these measurements being less than 400 copies/ml over several years as suggested by a prior study [41] . The elite controllers were divided into two groups based on their longitudinal CD4% over a median of 6.2 years of follow-up. These were EC hi (pVL low to undetectable, median CD4% > 40, n ¼ 9) and EC lo (pVL low to undetectable, median CD4% 40, n ¼ 7). We compared the two elite controller groups against two comparator groups, that is HIV seronegative and HIV-1 noncontrollers (pVL > 10 000 copies/ml, n ¼ 9). Local institutional review board approval was obtained and all participants consented to this study.
Polychromatic flow cytometry
Cryopreserved PBMC were thawed and surface stained using fluorochrome-conjugated antibodies in three different panels in parallel to assess ex vivo expression levels of activation, exhaustion, immunosenescence and memory markers. The cells were stained with LIVE/ DEAD cell dye (Invitrogen, Life Technologies, Carlsbad, California, USA), washed, and surface labeled with the following antibodies: Panel 1 -anti-CD3 (APC-eFluor 780, eBioscience, San Diego, California, USA), anti-CD4 (Qdot655, Invitrogen), anti-CD8 (V500, BD (Becton Dickinson, Franklin Lakes, New Jersey, USA)), anti-CD45Ra (Brilliant Violet 421, BD), anti-CCR7 (PercpCy5.5, BD), anti-CD28 (PE, BD), anti-CD57 (FITC, BD), and anti-PD1 (APC, eBioscience); Panel 2 -anti-CD3, anti-CD4, anti-CD8, anti-CD38 (PE, BD), anti-HLADR (PercpCy5.5, BD), anti-CD73 (PECy7, BD), anti-PD1, anti-CD160 (Alexa488, BD), and anti-TIM3 (Brilliant Violet 421, Biolegend, San Diego, California, USA); Panel 3 -anti-CD3, anti-CD14 (Alexa700, BD), anti-CD16 (FITC, BD), anti-HLADR, anti-CCR2 (Alexa647, BD), anti-CX3CR1 (PE, BD), and anti-CD11b (PECy7, BD). CCR7 staining was performed first by incubating cells at 378C for 15 min, followed by washing and staining for all other surface markers for 20 min at 48C. Samples were washed, fixed in 2% paraformaldehyde and analyzed on a BD flow cytometer (LSR II). At least 1 00 000 CD3 þ events were acquired and the data were analyzed using FlowJo software (version 9.7, Tree Star Inc., Ashland, Oregon, USA). Frequency and mean fluorescence intensity data were analyzed and compared for all single markers. Boolean combination gating was performed to analyze combinations of three or more markers.
Soluble CD14 ELISA Plasma levels of sCD14 were quantified using a Human sCD14 Quantikine ELISA kit (R&D Systems, Minneapolis, Minnesota, USA). Briefly, plasma samples were prefiltered, UV inactivated, diluted 1 : 200 and incubated in plates precoated with antihuman sCD14 antibody for 3 h. After washing, plate-bound sCD14 was detected with an horseradish peroxidase-conjugated antisCD14 antibody for 1 h. The plate was developed using tetramethylbenzidine for 30 min before 2N H 2 SO 4 stop solution was added. Plate-bound sCD14 was quantified by measuring the absorbance at 450 nm with a wavelength correction at 540 nm using a BioTek Synergy HT reader. Plasma levels of sCD14 were interpolated from the standard curve using Microsoft Excel software.
Statistical analyses
For the categorical variables, both chi-square and Fisher's exact tests were performed.
For continuous variables the nonparametric Kruskal-Wallis test was used to assess differences among the four groups. The expression of markers between the groups was compared pairwise using the nonparametric Mann-Whitney test and covariation between two variables was quantified using the nonparametric Spearman correlation.
Clinical data (CD4% and absolute CD4 þ cell count) for each individual at multiple longitudinal time points were obtained. The mean values for each of the above clinical data for the EC hi and EC lo groups at each time point were graphed and fit with a linear regression line. The slopes of the regression lines were compared using ANCOVA. The overall change in these two measures from the first to last available time points was also calculated and the medians for each group were compared using nonparametric Mann-Whitney test. All analyses were performed using Prism software (version 6, GraphPad Software Inc., La Jolla, California, USA).
Results
Heterogeneity in the frequency and magnitude of CD4 R T cells in the elite controller group We categorized two elite controllers groups based on the median CD4% for each individual and whether that individual maintained their categorical CD4% over time.
We chose 40% CD4 þ as a cut-off since the median of the elite controller group as a whole was 41% and designated the two groups as EC hi (CD4% > 40) and EC lo (CD4% 40).
After a median follow-up of 6.2 years, clinical data revealed clear heterogeneity between the two elite controllers groups ( Fig. 1 ) with respect to absolute CD4 þ cell counts and CD4%. Although there was significant overlap for the median absolute CD4 þ T-cell count for both EC hi and EC lo groups, there were distinct differences in the median CD4% as expected ( Fig. 1a and b). Although most individuals demonstrated relatively stable CD4% and absolute count over time ( Fig. 1c and  d ), there was a trend for a decrease in CD4% ( Fig. 1c , P ¼ 0.067) in the EC lo group compared with the EC hi group.
Furthermore, pVL was lower in the EC hi group and with fewer intermittent viral blips compared with the EC lo group (supplementary Figure 1 , http://links.lww.com/ QAD/A768). Given these clinical distinctions among the two elite controllers groups, we evaluated whether a higher CD4% equated with lower levels of expression of cellular markers of activation and exhaustion. Reduced T-cell activation in the EC hi group Since immunologic markers such as CD38 and HLA-DR have been shown to be predictive of HIV disease progression [42, 43] , we assessed their surface expression in each of the four groups of participants. A comparative analysis of the elite controllers groups revealed that the EC hi CD8 þ T cells expressed lower HLA-DR þ (median 5 vs. 33%, P < 0.0001) and CD38 þ HLA-DR þ (2 vs. 17%, P ¼ 0.0002) compared with the EC lo group (Fig. 2a ). Similar data were also observed in the CD4 þ T cells ( Fig. 2b) . Additionally, for CD8 T cells, a trend for lower expression of CD38 þ for the EC hi was observed (23 vs. 38%, P ¼ 0.058; Fig. 2a ). For both the immune activation markers, EC hi were indistinguishable from the seronegatives with regards to the CD8 þ and CD4 þ T cells. Additional differences in marker expression were also seen when either of the elite controllers groups were compared with the seronegative and noncontrollers (supplementary Tables 2 and 3 , http://links.lww.com/ QAD/A768).
An inverse correlation was previously reported between absolute CD4 þ cell counts and immune activation of T cells [10] . Similarly, in our elite controllers cohort, negative correlations were observed between CD4% and CD38 þ HLA-DR þ expression on CD8 þ T cells (r ¼ -0.8306, P < 0.0001; Fig. 2c ) and CD4 þ T cells (r ¼ -0.7742, P ¼ 0.0002; Fig. 2d ). Correlations between CD8 þ T-cell activation and CD4% were not observed for the noncontrollers group (data not shown).
Lower frequency of terminally differentiated CD8 R T cells in the EC hi group
The proportion of T cells in various stages of maturation can be perturbed by alterations in viral load [44] . To evaluate whether CD4% impacted skewing of these populations, we characterized CD4 þ and CD8 þ T-cell memory subsets by surface expression of CCR7, CD45RA and CD28 and defined as naive with the EC lo group (P ¼ 0.03, supplementary Figure 2 , http://links.lww.com/QAD/A768). Additionally, the EC hi group had higher frequency of naive CD8 þ T cells compared with EC lo (P ¼ 0.05). Therefore, overall, the EC hi had a less differentiated CD8 þ T-cell phenotype than the EC lo group.
Reduced expression of exhaustion markers PD-1 and CD160 on T cells in the EC hi group
We evaluated the expression of three exhaustion markers that are commonly used to determine this phenotype, that is PD-1, CD160 and TIM-3 [45] . The EC hi had decreased PD-1 þ (20 vs. 30%, P ¼ 0.0418), CD160 þ (21 vs. 63%, P ¼ 0.003) and CD160 þ , PD-1 þ (5 vs. 17%, P ¼ 0.003) compared with EC lo on the CD8 þ T cells ( Fig. 3a and c) . A similar pattern of PD1 þ and CD160 þ expression was also seen in CD4 þ T cells (P ¼ 0.006) ( Fig. 3b and d) . The EC hi also had lower mean fluorescence intensity of PD-1 þ on CD8 þ (4297 vs. 4854, P ¼ 0.006) and CD4 þ T cells (4641 vs. 5041, P ¼ 0.04) compared with EC lo . Details of other marker combinations that were different between all groups are shown in supplementary Tables 2 and 3, http:// links.lww.com/QAD/A768.
Lower expression of immunosenescent (CD57) and increased expression of costimulatory molecules (CD28 and CD73) on CD8 R T cells in the EC hi group
Persistent viral infections such as HIV lead to increased accumulation of cells that display a CD28and CD57 þ phenotype due to persistent antigenic stimulation [46] [47] [48] . We therefore assessed whether the T cells in the EC hi group had a higher proportion of functionally responsive cells. As expected, CD8 þ T cells from the EC hi revealed a phenotype of decreased T-cell senescence and increased costimulatory molecule expression. The EC hi CD8 þ T cells had markedly lower frequency of CD57 þ (median 22 vs. 45%, P ¼ 0.004), higher CD28 þ (80 vs. 36%, P ¼ 0.003), higher CD28 þ CD57 -(71 vs. 27%, P ¼ 0.0003), and higher CD73 þ (36 vs. 8%, P ¼ 0.005) than EC lo (Fig. 4a ). In each case, EC hi were similar to seronegatives, whereas the EC lo were comparable to noncontrollers. Additional data for the inter-group comparisons is shown in supplementary Tables 2 and 3, http://links.lww.com/QAD/A768.
A prior publication showed an inverse correlation between CD73 þ expression and CD8 þ T-cell activation [13] . We too observed a negative correlation for the combined elite controllers group which was most likely driven by the EC hi group (Fig. 4b ). However, we did not see a correlation for either the seronegative or noncontrollers although there was a trend in the latter group ( Fig. 4c and d) .
Lower frequency of circulating inflammatory monocytes in the EC hi group Monocyte subpopulations were defined into classical (CD14 þþ CD16 -), intermediate / inflammatory (CD14 þþ CD16 þ ), and nonclassical / patrolling (CD14 þ CD16 þþ ) as previously described [49] . The EC hi subgroup showed decreased frequency of intermediate / inflammatory monocytes compared with the EC lo (median 1 vs. 2.2%, P ¼ 0.001, supplementary Figure 3 , http://links.lww.com/QAD/A768). This inflammatory subset also expressed lower median levels of HLA-DR when compared with EC lo (95.7 vs. 98.3%, P ¼ 0.033)data not shown. The frequency and activation levels for the other two monocyte subsets were similar among the elite controllers groups -supplementary Figure 3 , http:// links.lww.com/QAD/A768. Plasma levels of sCD14 were not different among the two elite controllers groups or the elite controllers overall group compared with seronegative and noncontrollers.
Discussion
ART has significantly improved over the past several years allowing administration of potent, simple regimens that are well tolerated and associated with minimal sideeffects. However, even patients with asymptomatic HIV infection and normal absolute CD4 þ T-cell counts have evidence of immune activation, a parameter associated with disease progression [10] . This information has led many providers to recommend treatment for all HIV positive patients regardless of their CD4 þ T-cell counts [50] . Elite controllers, who appear to maintain control of their HIV, are a rare group of individuals for whom the risks of ART may outweigh the benefits, as the latter may not be obvious without candid evidence of disease progression. Nevertheless, several studies have demonstrated that elite controllers also have evidence of immune activation and may benefit from ART as well. Such prior studies have generally considered elite controllers to represent a single group; however, such patients actually demonstrate heterogeneity -clinically, genetically, and immunologically [32] [33] [34] [35] [36] . In this study, despite the small sample size of the elite controllers cohort, we have shown that CD4% is an easily quantifiable benchmark for gauging the clinical heterogeneity in the elite controllers group as reflected by the stark differences in the immune phenotypes observed. Specifically, our data demonstrated that CD8 þ T cells from elite controllers with high CD4% (EC hi ) have expression levels of markers of immune activation, senescence, and exhaustion that are comparable to HIV seronegative controls and decreased when compared with HIV-infected patients including elite controllers with low CD4% (EC lo ) and noncontrollers. Future studies will assess the clinical outcome from ART in elite controllers with low CD4%.
Some of the heterogeneity in elite controllers may stem from the varied clinical definitions that have been used to identify elite controllers [51] . As recommended in a recent review of elite controllers literature, we used the criteria of elite controllers having either consecutive undetectable HIV-RNA measurements for greater than six months or with greater than 90% of these measurements being less than 400 copies/ml over several years [41] . Although the pVL is largely undetectable in our two elite controllers groups, viral blips were less frequently observed in the EC hi group. Hence it is possible that a lack of these episodes of intermittent viremia may contribute to the increased frequency of naive and lower proportion of terminally differentiated cells seen in the EC hi group. Since viral blips [52] have also been associated with activated CD8 þ T cells, it is not surprising that the T cells in the EC hi group are less activated and in part responsible for the preserved CD4% over time. Thus, only the EC lo may benefit from ART to prevent sporadic viremic episodes.
A prior study showed that HIV controllers had higher T-cell activation than seronegative donors [10] . There are additional studies that have shown the presence of immune activation in elite controllers [29, 53] . However our data show that excess T-cell activation is only present in the EC lo group and not among the EC hi individuals. This was not influenced by racial composition differences between the two elite controllers groups since similar levels of immune activation and exhaustion markers were noted between whites and African-Americans (EC lo and noncontrollers); data not shown. One likely explanation for the discrepancy between our elite controllers work and those by other groups could be that prior studies were perhaps largely based upon elite controllers patients with low CD4%.
Evaluation of numerous immune indices showed that the EC hi group demonstrates several hallmark characteristics of preserved immune integrity. Notably, these EC hi individuals maintained a higher CD4% that was associated with lower expression of multiple markers of activation and exhaustion. Additionally, in this group, maintenance of CD28 expression, a costimulatory molecule which is commonly reduced during chronic HIV infection was retained. A recent study found that CD73, a coactivator of T cells [13] , was elevated in all elite controllers. However our data show that this is only observed for the EC hi group and therefore cumulatively indicates that the EC hi group manifests a phenotype of functionally responsive T cells that is similar to healthy seronegative adults.
Immune activation has been associated with reduced CD4 þ T-cell recovery. Although we did not see differences in the sCD14 between the two elite controllers groups in our limited sample size, it is likely that EC hi have lower levels of products of microbial translocation, due to less severe CD4 þ depletion early in infection and lower activation-induced cell death, both of which could contribute to the CD4% preservation in this group. In contrast, the EC lo behave more like the immunologic nonresponders on ART [54] who have been shown to have increased microbial translocation and immune activation which may drive CD4 þ depletion and hence the failure to normalize CD4 þ T-cell counts. Interestingly in patients with idiopathic CD4 þ lymphocytopenia (ICL), increased levels of LPS were observed highlighting a potential association between translocation of microbial products, immune activation and altered CD4 þ T-cell homeostasis [55] .
Recent studies have highlighted the usefulness of CD4 þ / CD8 þ ratio for gauging immune restoration [47, 56] . In our study, we observed a strong correlation between CD4% and the CD4 þ /CD8 þ ratio among elite controller individuals (r ¼ 0.84; P value ¼ <0.0001). Furthermore, the median CD4 þ /CD8 þ ratio for the EC hi mirrored the HIV seronegatives whereas the EC lo and the HIV noncontrollers exhibited a similar ratio. Additionally, significant correlations were observed when either the CD4% (r ¼ -0.79, P ¼ 0.0001) or the CD4 þ /CD8 þ ratio (r ¼ -0.80, P ¼ <0.0001) was compared with % CD8 þ T-cell immune activation (HLADR þ CD38 þ ).
In summary, our data suggest that a subgroup of elite controllers with preserved CD4 þ T-cell percentages may be immunogically normal and would not derive clinical benefit from ART. In contrast, elite controllers with evidence of CD4 þ depletion may well benefit from the implementation of ART to suppress low-level viremia and reduce immune activation and exhaustion. Although our findings based on a small sample size cannot be used to dictate treatment choices, these data can inform the design of future studies focused on elite controllers and on immunomodulatory therapies that are aimed at improving the immune function in chronic HIV infection. Our findings further support CD4% as an important marker in subdividing elite controllers to better evaluate results from future studies designed to determine the need for ART in this group of individuals.
